Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

In less than 10 years, melanoma treatment has been revolutionized with the approval of
tyrosine kinase inhibitors and immune checkpoint inhibitors, which have been shown to …

Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

Aberrant activation of signaling through the RAS–RAF–MEK–ERK (MAPK) pathway is
implicated in numerous cancers, making it an attractive therapeutic target. Although BRAF …

Malignant melanoma is a neoplasm originating in the melanocytes in the skin. Although
malignant melanoma is the third most common cutaneous cancer, it is recognized as the …

Simple Summary To date, one of the reference therapies for the treatment of mutated BRAF
metastatic melanoma is based on the combination of BRAF and MEK inhibitors. Although …

Cutaneous melanoma (CM) is an increasingly significant public health concern. Due to
alarming mortality rates and escalating incidence, it is crucial to understand its etiology and …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis
and poor therapeutic response to current chemotherapy regimens in unselected patient …

Genistein is one of the main components of soy-based foods, which are widely known for
their many benefits, including anti-cancer, anti-inflammatory, and antioxidant effects. In this …

The incidence of cutaneous melanoma (CM) has been increasing annually worldwide. In
this study, we identify that MrgprF, a MAS related GPR family member, is decreased in …